Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis

This is a Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of MEDI9929 administered subcutaneously to adult subjects with moderate to severe Atopic Dermatitis. Subjects will be randomized in a 1:1 fashion and will be stratified at screening. Approximately 100 subjects are planned to be randomized at approximately 35 sites in 6 countries

Inclusion Criteria:

• AD meeting Hanifin and Rajka criteria
• Age 18-75 years inclusive at screening
• Atopic dermatitis that affects greater than/equal to 10% body surface area
• Moderate to severe AD
• Effective birth control in line with protocol details

Exclusion Criteria:

• Active dermatologic conditions which may confuse the diagnosis of Atopic Dermatitis
• Hepatitis B, C or HIV
• Pregnant or breastfeeding
• History of anaphylaxis following any biologic therapy
• History of clinically significant infections within 4 weeks prior to Visit 3
• Diagnosis of helminth parasitic infection within 6 months to screening
• History of Cancer except basal cell
• Receipt of any marketed or investigational biologic agent within 4 months to visit 3
• Any clinically relevant abnormal finding
• Major surgery within 8 weeks prior to Visit 1